Celldex Therapeutics (NASDAQ:CLDX) reported quarterly losses of $(1.18) per share which beat the analyst consensus estimate of $(1.20) by 1.67 percent. This is a 45.68 percent decrease over losses of $(0.81) per share from the same period last year. The company reported quarterly sales of $15.000 thousand which missed the analyst consensus estimate of $972.222 thousand by 98.46 percent. This is a 97.84 percent decrease over sales of $695.000 thousand the same period last year.